PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study

Bayard, Y; Omran, Heyder; Neužil, Petr; Thuesen, Leif; Pichler, M; Rowland, Edward; Ramondo, Angelo; Rużyłło, Witold; Budts, Werner; Montalescot, Gilles; Brugada, Pedro; Serruys, Patrick W.; Vahanian, Alec; Piéchaud, Jean François; Bartorelli, Antonio L.; Marco, Jean; Probst, Peter; Kuck, Karl Heinz; Ostermayer, Stefan; Büscheck, Franziska; Fischer, Evelyn; Leetz, Michaela; Sievert, Horst

doi:10.4244/eijv6i2a35

Cited by 157 publications

(89 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…He attended the first implantation of his Percutaneous Left Atrial Appendage Transcatheter Occluder (PLAATO, abandoned, Medtronic, Mansfield, MA, USA) on August 30, 2001, by Horst Sievert in Frankfurt, Germany [4]. The results of patients treated with this device were superior to what could be expected with VKA [5,6]. T he procedure itself, however, was rather intricate, partly due to bulky catheters.…”

Section: Te Chniques Of Left Atrial Appendage Occlusionmentioning

confidence: 91%

Left atrial appendage device closure as non-pharmacological prevention of thromboembolism in atrial fibrillation

2014

Cardiovasc Med

View full text Add to dashboard Cite

SummaryThe fact that non-valvular (non-rheumatic) atrial fibrillation creates detectable thrombi in 17% of patients without oral anticoagulation and that 16% of the 17% (over 90% relatively) reside in the left atrial appendage (LAA), suggest that patients without an LAA or with an occluded LAA do not need oral anticoagulation. This has already led to surgical LAA exclusion for decades and to catheter-based LAA occlusion for the past 13 years.Currently 5 different technical approaches are approved in European countries, but only 2 are widely used, the Amplatzer and the Watchman devices. With the latter, randomised data showed superiority in terms of embolism protection, bleeding, and survival compared to vitamin K antagonists (VKA) after 4 years in a randomised trial. The clinical results in thousands of patients with Watchman and Amplatzer occluders suggest, moreover, that they are at least competitive with non-VKA oral anticoagulants. Non-pharmacological prevention of thromboembolism with device implantation or, in case of another indication for heart surgery during that intervention, may be discussed with every patient with atrial fibrillation as an alternative to oral anticoagulation.

show abstract

Section: Te Chniques Of Left Atrial Appendage Occlusionmentioning

confidence: 91%

Left atrial appendage device closure as non-pharmacological prevention of thromboembolism in atrial fibrillation

2014

Cardiovasc Med

View full text Add to dashboard Cite

show abstract

“…It is no longer available as the manufacturer discontinued production for financial reasons despite initially promising clinical results. [131][132][133][134] The intellectual property rights for PLAATO were acquired by Atritech in 2007 during their development of the WATCHMAN® program. 135 …”

Section: Plaatomentioning

confidence: 99%

Left Atrial Appendage Exclusion for Atrial Fibrillation

Syed

DeSimone

Friedman

et al. 2016

Heart Failure Clinics

View full text Add to dashboard Cite

“…The PLAATO feasibility study in North America 112) enrolled 64 patients who were contraindicated for warfarin treatment The mean CHADS2 score of the patients was 2.9. The annual stroke rate was 3.8% (anticipated stroke rate was 6.6%) corresponding to 50% estimated stroke reduction.…”

Section: Alternative Treatment Strategiesmentioning

confidence: 99%

Recent Progress in Antithrombotic Therapy for Atrial Fibrillation

Velu

Lip

2011

JAT

View full text Add to dashboard Cite

Atrial fibrillation (AF) is becoming a major health care burden as elderly populations increase. The increased risk of stroke and thromboembolisms in patients with AF is well documented and anticoagulation with adjusted-dose warfarin is highly effective in reducing stroke risk, being superior to antiplatelet agents. Despite recognition of the epidemiological problem and the sound evidence base for thromboprophylaxis, as well as major guidelines recommending treatment, anticoagulation use is still suboptimal, given the dis-utility and limitations associated with warfarin.Recent developments in thromboprophylaxis for AF include efforts for better risk stratification for predictions of thromboembolic risk. Constant efforts are underway to develop newer, less cumbersome, alternatives to warfarin with similar (or better) efficacy. This review article provides an overview of the recent progress made, the potential challenges involved and the future of these therapeutic approaches.Atheroscler Thromb, 2011; 18:257-273.

show abstract

PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study

Cited by 157 publications

References 20 publications

Left atrial appendage device closure as non-pharmacological prevention of thromboembolism in atrial fibrillation

Left atrial appendage device closure as non-pharmacological prevention of thromboembolism in atrial fibrillation

Left Atrial Appendage Exclusion for Atrial Fibrillation

Recent Progress in Antithrombotic Therapy for Atrial Fibrillation

Contact Info

Product

Resources

About